Business
Xeris Biopharma’s Resilience Shines Despite Tariff Turbulence
Tariffs on April 2: Big Talk, Limited Bite for Pharma Investors braced for the worst when President Trump announced “reciprocal tariffs” on April 2, 2025 – an aggressive move that some early reports hinted could mean a blanket 25% duty on all imports. In fact, Trump had publicly floated imposing 25% (or higher) tariffs on…
Fireside Chat with Paul Edick – Xeris Biopharma – $XERS
Fireside chat with Paul Edick – CEO of Xeris Biopharma – $XERS
What Lies Ahead For Xeris Biopharma In 2022
Jan. 1 PDUFA for Recorlev, Merck collaboration, Levothyroxine Phase 1, EIH Phase 2, and growing sales for Gvoke and Keveyis; Xeris has great potential for 2022.
BlackRock Form 8.3s
Source
Xeris enters into $71M Olguo commercialization agreement with Tetris Pharma
Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe Up to $71 million in time- and milestone-based payments, plus royalties on sales Agreement covers 32 countries First launch expected in Q4 2021 in UKJuly 19, 2021 08:00 AM Eastern Daylight Time CHICAGO–(BUSINESS WIRE)–Xeris Pharmaceuticals, Inc. (Nasdaq:…